Response Prediction Model of Atezolizumab plus Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma: Multicenter Retrospective Study
Oncology · 2023
DOI: 10.1159/000531317 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Oncology, 2023. Verfasst von Masaki Ueno und 10 weiteren Autor:innen. Beteiligte Einrichtung: Second Department of Surgery, Wakayama Medical University, Wakayama, Japan. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 37 Literaturangaben.
Abstract (Originalsprache)
Introduction
Atezolizumab plus bevacizumab (ATZ+BV) treatment has become the first-line regimen for unresectable hepatocellular carcinoma (u-HCC). Prediction of response to it might be clinically beneficial. Using peripheral blood parameters, we aimed to construct a prediction model for ATZ+BV treatment.
Methods
Clinical records of 119 patients with u-HCC treated by ATZ+BV were retrospectively analyzed. The primary outcome measurement was defined as any-size reduction at the initial image evaluation. Using baseline values of peripheral blood parameters, a prediction model was constructed by univariate and multivariate logistic regression analysis. Validation was performed internally by bootstrap method.
Results
The primary outcome was achieved in 46 patients. Univariate analysis showed that C-reactive protein (CRP), alpha-fetoprotein (AFP), des-gamma-carboxy prothrombin (DCP), neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (PLR) were possible predictors. CRP and DCP, and NLR and PLR had correlation (correlation coefficient >0.3), so we used CRP and NLR as representative factors, respectively. Multivariate analysis constructed the following prediction model: Logit = 1.62–0.61×[CRP] −0.38×[Log10AFP] −0.37×[NLR]. Bootstrapped median (95% confidence interval) of coefficients of CRP, Log10AFP, NLR were −0.64 (−1.46 ∼ −0.11), −0.40 (−0.82 ∼ −0.03), and −0.38 (−0.74 ∼ −0.05), respectively. The area under the receiver operating characteristic curve (95% confidence interval) was 0.73 (0.60–0.80). Median overall survival of the favorably and unfavorably predicted groups were 17.0 and 11.0 months (p = 0.03), respectively.
Discussion
In patients with u-HCC treated by ATZ+BEV, a prediction model constructed using baseline values of CRP, AFP, and NLR had impact on any-size reduction at the initial image evaluation and on prognosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Second Department of Surgery, Wakayama Medical University, Wakayama, Japan.
- Department of Surgery, Kansai Medical University Hirakata Hospital, Osaka, Japan.
- Department of Surgery, Shiga University of Medical Science, Otsu, Japan.
- Second Department of Internal Medicine, Wakayama Medical University, Wakayama, Japan.
- Third Department of Internal Medicine, Kansai Medical University Hirakata Hospital, Osaka, Japan.
- Department of Pharmacy, Kansai Medical University Hirakata Hospital, Osaka, Japan.
Zitieren
APA
Ueno, M., Kosaka, H., Iida, H., Ida, Y., Aoi, K., Mori, H., Miyamoto, A., Nishida, Y., Hayami, S., Kawai, M., & Kaibori, M. (2023). Response Prediction Model of Atezolizumab plus Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma: Multicenter Retrospective Study. Oncology. https://doi.org/10.1159/000531317
Vancouver
Ueno M, Kosaka H, Iida H, Ida Y, Aoi K, Mori H, et al. Response Prediction Model of Atezolizumab plus Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma: Multicenter Retrospective Study. Oncology. 2023. doi:10.1159/000531317
BibTeX
@article{Ueno2023,
author = {Ueno, Masaki and Kosaka, Hisashi and Iida, Hiroya and Ida, Yoshiyuki and Aoi, Kazunori and Mori, Haruki and Miyamoto, Atsushi and Nishida, Yuko and Hayami, Shinya and Kawai, Manabu and Kaibori, Masaki},
title = {Response Prediction Model of Atezolizumab plus Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma: Multicenter Retrospective Study},
journal = {Oncology},
year = {2023},
doi = {10.1159/000531317}
}
EUVIMED